Biosig Technologies (NASDAQ:STEX) Rating Lowered to “Strong Sell” at Wall Street Zen

Biosig Technologies (NASDAQ:STEX) was downgraded by Wall Street Zen from a “hold” rating to a “strong sell” rating in a research note issued on Sunday.

Separately, Weiss Ratings started coverage on Biosig Technologies in a research report on Friday, January 23rd. They set a “sell (d-)” rating for the company. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Biosig Technologies presently has an average rating of “Sell”.

Biosig Technologies Trading Down 2.6%

NASDAQ:STEX opened at $1.13 on Friday. The firm has a market capitalization of $201.73 million, a PE ratio of -0.12 and a beta of 1.90. The firm has a 50-day simple moving average of $2.20. Biosig Technologies has a 1 year low of $0.40 and a 1 year high of $14.11.

Biosig Technologies (NASDAQ:STEX) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($8.23) earnings per share for the quarter.

Insider Buying and Selling at Biosig Technologies

In other Biosig Technologies news, CIO Mitchell Young Williams acquired 51,511 shares of the company’s stock in a transaction on Friday, January 23rd. The shares were purchased at an average price of $3.03 per share, for a total transaction of $156,078.33. Following the completion of the purchase, the executive directly owned 1,051,511 shares of the company’s stock, valued at approximately $3,186,078.33. This represents a 5.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Frank Giustra acquired 100,000 shares of the company’s stock in a transaction on Wednesday, February 4th. The stock was acquired at an average price of $3.17 per share, for a total transaction of $317,000.00. Following the purchase, the insider directly owned 1,278,205 shares of the company’s stock, valued at approximately $4,051,909.85. This trade represents a 8.49% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 1,267,011 shares of company stock worth $3,825,628 over the last 90 days. Company insiders own 52.73% of the company’s stock.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.